Key Takeaways
- • Irish SME venture capital funding collapsed to €221.7m in Q1 2026, representing a 58% year-on-year decline from a record €500m+ in Q1 2025, according to the Irish Venture Capital Association's Venture Pulse survey.
- • Life sciences dominated fundraising activity at over 50% of total deal value, with fintech at 13% and software at 12%, while pure-play AI companies remain absent from significant Irish VC rounds despite global AI market dominance.
- • Deal fragmentation accelerated, with mid-market transactions showing severe contraction: deals valued €5m–€10m fell 62% and deals in the €3m–€5m range dropped 77% quarter-over-quarter.
- • Neurent Medical's €62.5m raise and Aerska's €33m fundraise represented the largest transactions in the quarter, highlighting concentrated deal flow in the Irish market.
- • IVCA Director General Sarah-Jane Larkin flagged structural vulnerability: Ireland's small market size and significant reliance on overseas capital create exposure to international VC cycle downturns.
Summary
Venture capital funding to Irish small and medium-sized enterprises contracted sharply in the first quarter of 2026, with total fundraising reaching €221.7m—a 58% decline compared to the prior year's record opening quarter, according to the Irish Venture Capital Association's Q1 Venture Pulse survey published May 25, 2026.
While the baseline comparison reflects Q1 2025's exceptionally strong performance at over €500m, IVCA Director General Sarah-Jane Larkin characterized the current decline as a "slight warning sign and a cause for concern." She emphasized that the contraction cannot be dismissed as mere cyclicality, pointing instead to deeper structural issues affecting Ireland's venture ecosystem. "The quarter last year was a record first quarter of over €500m—so we're comparing it to a very strong quarter last year," Larkin stated. "Notwithstanding that, there are some warning signs over the last number of quarters that show Ireland is a very small market and we have a significant exposure to overseas capital."
Life sciences transactions dominated the funding landscape, accounting for over half of total deal value, followed distantly by fintech at 13% and software firms at 12%. Notably, despite artificial intelligence's commanding position in global VC markets, Ireland has yet to produce a pure-play AI company attracting material funding rounds. Larkin noted that AI adoption is widespread across Irish SMEs as embedded functionality rather than as a standalone focus, stating that "any company that is raising funding has to have some level of AI embedded in their product or service to achieve funding."
The contraction manifested most severely at mid-market deal sizes. Transactions valued between €5m and €10m contracted 62%, while the €3m–€5m segment experienced a steeper 77% decline. The largest transaction in the quarter was Neurent Medical's €62.5m raise, followed by Aerska's €33m fundraise, underscoring concentrated deal flow within Ireland's limited VC landscape.
While the baseline comparison reflects Q1 2025's exceptionally strong performance at over €500m, IVCA Director General Sarah-Jane Larkin characterized the current decline as a "slight warning sign and a cause for concern." She emphasized that the contraction cannot be dismissed as mere cyclicality, pointing instead to deeper structural issues affecting Ireland's venture ecosystem. "The quarter last year was a record first quarter of over €500m—so we're comparing it to a very strong quarter last year," Larkin stated. "Notwithstanding that, there are some warning signs over the last number of quarters that show Ireland is a very small market and we have a significant exposure to overseas capital."
Life sciences transactions dominated the funding landscape, accounting for over half of total deal value, followed distantly by fintech at 13% and software firms at 12%. Notably, despite artificial intelligence's commanding position in global VC markets, Ireland has yet to produce a pure-play AI company attracting material funding rounds. Larkin noted that AI adoption is widespread across Irish SMEs as embedded functionality rather than as a standalone focus, stating that "any company that is raising funding has to have some level of AI embedded in their product or service to achieve funding."
The contraction manifested most severely at mid-market deal sizes. Transactions valued between €5m and €10m contracted 62%, while the €3m–€5m segment experienced a steeper 77% decline. The largest transaction in the quarter was Neurent Medical's €62.5m raise, followed by Aerska's €33m fundraise, underscoring concentrated deal flow within Ireland's limited VC landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.